12178 Federal Register / Vol. 72, No. 50 / Thursday, March 15, 2007 / Notices 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters To Be Discussed: The meeting will 

include the review, discussion, and 

evaluation of scientific merit of grant 

applications received in response to RFA 

DD07–006, ‘‘China-United States 

Collaborative, Population-Based Surveillance 

and Research Program for Maternal-Child 

and Family Health.’’

For Further Information Contact: Juliana 

Cyril, Ph.D., Scientific Review Administrator, 

Centers for Disease Control and Prevention, 

1600 Clifton Road NE, Mailstop D72, Atlanta, 

GA 30333, Telephone 404.639.4639. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: March 8, 2007. 

Elaine L. Baker, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E7–4744 Filed 3–14–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Childhood 

Agriculture Safety and Health 

Research, Request for Applications 

(RFA) OH 07–002 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting. 

Time and Date: 1 p.m.–3 p.m., April 

16, 2007 (Closed). 

Place: Teleconference. 

Status: The meeting will be closed to 

the public in accordance with 

provisions set forth in Section 552b(c) 

(4) and (6), Title 5 U.S.C., and the 

Determination of the Director, 

Management Analysis and Services 

Office, CDC, pursuant to Public Law 92–

463. 

Matters to be Discussed: The meeting 

will include the review, discussion, and 

evaluation of applications received in 

response to RFA OH 07–002, 

‘‘Childhood Agriculture Safety and 

Health Research.’’

Contact Person For More Information: 

Stephen Olenchock, Scientific Review 

Administrator, Office of Extramural 

Coordination and Special Projects, 

National Institute for Occupational 

Safety and Health, CDC, 1095 

Willowdale Road, Mailstop P–04, 

Morgantown, WV 26506, Telephone 

304–285–6271. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC 

and the Agency for Toxic Substances 

and Disease Registry. 

Elaine L. Baker, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E7–4745 Filed 3–14–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. 2006N–0472] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Substances 

Prohibited From Use in Animal Food or 

Feed; Animal Proteins Prohibited in 

Ruminant Feed 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a proposed collection of 

information has been submitted to the 

Office of Management and Budget 

(OMB) for review and clearance under 

the Paperwork Reduction Act of 1995. 

DATES: Fax written comments on the 

collection of information by April 16, 

2007. 

ADDRESSES: To ensure that comments on 

the information collection are received, 

OMB recommends that written 

comments be faxed to the Office of 

Information and Regulatory Affairs, 

OMB, Attn: FDA Desk Officer, FAX: 

202–395–6974. 

FOR FURTHER INFORMATION CONTACT: 

Denver Presley, Jr., Office of the Chief 

Information Officer (HFA–250), Food 

and Drug Administration, 5600 Fishers 

Lane, Rockville, MD 20857, 301– 827–

1472. 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, FDA 

has submitted the following proposed 

collection of information to OMB for 

review and clearance. 

Substances Prohibited from Use in 

Animal Food or Feed; Animal Proteins 

Prohibited in Ruminant Feed—21 CFR 

589.2000(e)(1)(iv) (OMB Control 

Number 0910–0339)—Extension 

This information collection was 

established because epidemiological 

evidence gathered in the United 

Kingdom suggested that bovine 

spongiform encephalopathy (BSE), a 

progressively degenerative central 

nervous system disease, is spread to 

ruminant animals by feeding protein 

derived from ruminants infected with 

BSE. That regulation places general 

requirements on persons that 

manufacture, blend, process, and 

distribute products that contain or may 

contain protein derived from 

mammalian tissue, and feeds made from 

such products. 

In the Federal Register of December 4, 

2006 (71 FR 70409), FDA published a 

60-day notice requesting public 

comment on the information collection 

provisions. No comments were received. 

The respondents for this collection of 

information are manufacturers and or 

distributors of products that contain or 

may contain protein derived from 

mammalian tissues and feeds made 

from such products. 

TABLE 1.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1

21 CFR Section No. of 

Recordkeepers 

Annual Frequency 

per Recordkeeping 

Total Annual 

Records 

Hours per 

Record Total Hours 

589.2000(e)(1)(iv) 400 1 400 14 5,600 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 


rmajette on PROD1PC67 with NOTICES
Federal Register / Vol. 72, No. 50 / Thursday, March 15, 2007 / Notices 12179 

Dated: March 7, 2007. 

Jeffrey Shuren, 

Assistant Commissioner for Policy. 

[FR Doc. E7–4685 Filed 3–14–07; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket Nos. 2006M–0384, 2006M–0385, 

2006M–0386] 

Medical Devices Regulated by the 

Center for Biologics Evaluation and 

Research; Availability of Summaries of 

Safety and Effectiveness Data for 

Premarket Approval Applications 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is publishing a 

list of premarket approval applications 

(PMAs) that have been approved by the 

Center for Biologics Evaluation and 

Research (CBER). This list is intended to 

inform the public of the availability 

through the Internet and the FDA’s 

Division of Dockets Management of 

summaries of safety and effectiveness 

data of approved PMAs. 

ADDRESSES: Submit written requests for 

copies of summaries of safety and 

effectiveness data to the Division of 

Dockets Management (HFA–305), Food 

and Drug Administration, 5630 Fishers 

Lane, rm. 1061, Rockville, MD 20852. 

Please include the appropriate docket 

number as listed in tables 1 and 2 of this 

document when submitting a written 

request. See the SUPPLEMENTARY

INFORMATION section for electronic 

access to the summaries of safety and 

effectiveness data. 

FOR FURTHER INFORMATION CONTACT: 

Nathaniel L. Geary, Center for Biologics 

Evaluation and Research (HFM–17), 

Food and Drug Administration, suite 

200N, 1401 Rockville Pike, Rockville, 

MD 20852–1448, 301–827–6210. 

SUPPLEMENTARY INFORMATION: 

I. Background 

In the Federal Register of January 30, 

1998 (63 FR 4571), FDA published a 

final rule that revised 21 CFR 814.44(d) 

and 814.45(d)) to discontinue individual 

publication of PMA approvals and 

denials in the Federal Register, 

providing instead to post this 

information on the Internet at http:// 

www.fda.gov. In addition, the 

regulations provide that FDA publish a 

quarterly list of available safety and 

effectiveness summaries of PMA 

approvals and denials that were 

announced during the quarter. FDA 

believes that this procedure expedites 

public notification of these actions 

because announcements can be placed 

on the Internet more quickly than they 

can be published in the Federal 

Register, and FDA believes that the 

Internet is accessible to more people 

than the Federal Register. 

In accordance with section 515(d)(4) 

and (e)(2) of the Federal Food, Drug, and 

Cosmetic Act (the act) (21 U.S.C. 

360e(d)(4) and (e)(2)), notification of an 

order approving, denying, or 

withdrawing approval of a PMA will 

continue to include a notice of 

opportunity to request review of the 

order under section 515(g) of the act. 

The 30-day period for requesting 

administrative reconsideration of an 

FDA action under § 10.33(b) (21 CFR 

10.33(b)) for notices announcing 

approval of a PMA begins on the day the 

notice is placed on the Internet. Section 

10.33(b) provides that FDA may, for 

good cause, extend this 30-day period. 

Reconsideration of a denial or 

withdrawal of approval of a PMA may 

be sought only by the applicant; in these 

cases, the 30-day period will begin 

when the applicant is notified by FDA 

in writing of its decision. 

The following is a list of PMAs 

approved by CBER for which summaries 

of safety and effectiveness data were 

placed on the Internet from March 1, 

2006, through June 30, 2006, and from 

July 1, 2006, through September 30, 

2006. There were no denial actions 

during either period. The list provides 

the manufacturer’s name, the product’s 

generic name or the trade name, and the 

approval date. 

TABLE 1.—LIST OF SUMMARIES OF SAFETY AND EFFECTIVENESS DATA FOR APPROVED PMAS MADE AVAILABLE MARCH

1, 2006, THROUGH JUNE 30, 2006 

PMA No./Docket No. Applicant Trade Name Approval Date 

BP050009/0/2006M–0384 Chembio Diagnostic Systems, Inc. SURE CHECK HIV 1/2 ASSAY May 25, 2006 

BP050010/0/2006M–0385 Chembio Diagnostic Systems, Inc. HIV 1/2 STAT–PAKT ASSAY May 25, 2006 

TABLE 2.—LIST SUMMARIES OF SAFETY AND EFFECTIVENESS DATA FOR APPROVED PMAS MADE AVAILABLE JULY 1, 

2006, THROUGH SEPTEMBER 30, 2006 

PMA No./Docket No. Applicant Trade Name Approval Date 

BP050030/0/2006M–0386 Bayer Healthcare LLC ADVIA Centaur HIV 1/0/2 Enhanced Assay May 18, 2006 

II. Electronic Access 

Persons with access to the Internet 

may obtain the documents at http:// 

www.fda.gov/cber/products.htm. 

Dated: March 5, 2007. 

Jeffrey Shuren, 

Assistant Commissioner for Policy. 

[FR Doc. E7–4677 Filed 3–14–07; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HOMELAND 

SECURITY 

National Communications System 

[Docket No. NCS–2007–0001] 

National Security Telecommunications 

Advisory Committee 

AGENCY: National Communications 

System, DHS. 

ACTION: Notice of partially closed 

advisory committee meeting. 

SUMMARY: The President’s National 

Security Telecommunications Advisory 

Committee (NSTAC) will be meeting by 

teleconference: the meeting will be 

partially closed. 

DATES: Thursday, March 29, 2007, from 

2 p.m. until 3 p.m. 


rmajette on PROD1PC67 with NOTICES